Windlas Biotech Ltd

Windlas Biotech Ltd has announced the closure of its trading window for company securities. This closure will be effective from July 1, 2026, and will remain in effect until 48 hours after the unaudited financial results for the quarter ended June 30, 2026, are publicly disclosed. This measure is in accordance with the company's internal code of conduct for regulating trading activities.

Windlas Biotech Ltd has announced the grant of stock options/units to eligible employees under the 'WBL Employee Stock Option Scheme 2023' (ESOS 2023) and 'Windlas Plan 2025'. The Nomination and Remuneration Committee approved the grant of 21,250 stock options/units under the Plan and 15,750 stock options under ESOS 2023 on May 21, 2026. The exercise price for ESOS 2023 options will be determined by the committee, with a discount of up to 25% from the market price. Units under Windlas Plan 2025 will be granted at face value of ₹5 per share.

Windlas Biotech Ltd reports strong FY26 results with revenue reaching ₹904 crores, a 19% YoY increase. CDMO revenue grew by 20% to ₹664 crores. Adjusted EBITDA rose by 26% to ₹121 crores, and adjusted PAT increased by 31% to ₹83 crores. EPS grew 8% YoY to ₹31.60. The company boasts a strong net liquidity of ₹251 crores and is net debt-free. Q4FY26 revenue stood at ₹238 crores, up 18% YoY, with adjusted EBITDA at ₹33 crores and adjusted PAT at ₹23 crores.

Windlas Biotech Ltd's Board of Directors approved the audited consolidated and standalone financial results for the year ended March 31, 2026. The board also recommended a final dividend of ₹6.30 per equity share (126% of face value ₹5). The dividend, if declared at the AGM, will be credited/dispatched within 30 days of the AGM's conclusion. The board meeting was held on May 21, 2026, from 2.45 P.M. to 4.20 P.M. The auditors, J C Bhalla & Co, issued unmodified opinions on the audited financial results.

Windlas Biotech Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board recommended a dividend of ₹6.30 per equity share of face value ₹5, subject to shareholder approval at the upcoming Annual General Meeting. The auditors, J C Bhalla & Co, issued unmodified opinions on the audited financial results. The board meeting commenced at 2.45 P.M. and concluded at 4.20 P.M.

Windlas Biotech Ltd. reported a temporary disruption in operations at certain manufacturing sites on May 18, 2026, due to a statewide labour unrest in Uttarakhand. Production was restored by the evening shift, and operations have resumed across all sites. The company does not anticipate any material impact on its operations, supply chain, or financial performance. Local authorities are working to restore normalcy, and the management is closely monitoring the situation.

Windlas Biotech Ltd. has completed the extinguishment of 4,70,000 fully paid-up equity shares with a face value of ₹5 each, pursuant to its buyback offer. The buyback process, initiated with a public announcement on April 18, 2026, concluded with the extinguishment confirmed by NSDL on May 18, 2026. Post-buyback, the paid-up equity share capital stands at 2,06,36,229 shares, amounting to ₹10,31,81,145.

Windlas Biotech Ltd has scheduled a Board of Directors meeting on May 21, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also consider the recommendation of a dividend, if any. The trading window has been closed since April 1, 2026, and will reopen 48 hours after the declaration of the financial results.

ICICI Prudential Mutual Fund sold 5,40,642 shares of Windlas Biotech Ltd, representing a 2.46% decrease in shareholding. This sale occurred between July 30, 2024, and May 13, 2026, leading to a total holding of 9,13,135 shares, or 4.33% of the company's equity. The shares were sold through open market transactions, and ICICI Prudential clarified that the investment is not aimed at seeking control of the company.

Windlas Biotech Limited has announced a buyback offer for up to 4,70,000 fully paid-up equity shares, each with a face value of ₹5. The buyback price is set at ₹1,000 per equity share, payable in cash, totaling an aggregate maximum amount not exceeding ₹47,00,00,000 (₹47 Crore), excluding transaction costs. This represents 2.23% of the company's existing total paid-up equity share capital. The buyback will be conducted through the 'Tender Offer' route on a proportionate basis. The Record Date for eligible shareholders is Friday, April 24, 2026. The Letter of Offer, dated April 27, 2026, is being dispatched to eligible shareholders by April 28, 2026. The offer size represents 9.80% of the aggregate of total paid-up share capital and free reserves, based on March 31, 2025 financials, adhering to the statutory limit.